 previous article in this issue | next article in this issue  |
|
Document Details : Title: Evaluation of a novel paclitaxel-eluting stent with a bioabsorbable polymeric surface coating in the porcine artery injury model Author(s): F. Ding , Z. Lu , R. Zou , Y. Zhang , Q. Guo , S. Li , J. Yang Journal: Acta Cardiologica Volume: 66 Issue: 6 Date: 2011 Pages: 765-772 DOI: 10.2143/AC.66.6.2136961 Abstract : Purpose: Drug-eluting stents (DES) are unique in allowing sustained release after a single short intervention. The challenge with DES still remaining is the optimal combination of a biocompatible drug-eluting matrix including an antiproliferative drug. We studied the role of a novel paclitaxel-eluting stent with a bioabsorbable polymer coating in preventing vascular restenosis in the porcine artery injury model. Material and methods: Bare metal stents (BMS); polymer-coated-only stents (POLY); and polymer-based paclitaxel-eluting stents (PACL) were randomly implanted in pig femoral arteries. The dose density of paclitaxel was 1 μg/mm2 with in vitro studies demonstrating a gradual elution over a course of 6 months. Results: After 1-, 3- and 6-month follow-up, respectively, the animals underwent angiographic restudy and were terminated for histomorphometrical and histopathological analyses. At 1 month, the PACL group had the lowest histological percent stenosis when compared to the BMS and POLY groups (20 ± 4% vs 39 ± 6% and 41 ± 6%, respectively, P < 0.05). At 3 months, the PACL group still presents the lowest level of histological percent stenosis among the three groups (27 ± 6% vs 50 ± 10% and 46 ± 5%, respectively, P < 0.01). Six months later, the PACL group showed a similar histological percent stenosis as the BMS and POLY groups (44 ± 9% vs 56 ± 11% and 53 ± 9%, respectively, P = 0.145). Conclusions: This study shows favourable vascular compatibility and efficacy for a novel DES to inhibit in-stent neointima formation and preserve lumen area in the porcine artery model. |
